Greg Daniel, PhD (@gregwdaniel) header
Greg Daniel, PhD (@gregwdaniel) profile picture

Greg Daniel, PhD

@gregwdaniel

Eli Lilly. former Deputy Director @DukeMargolis, former Brookings fellow. Editor-In-Chief, TIRS. Health policy. Opinions my own.

 Washington, DC
brookings.edu/experts/danielg
Joined August 2012
  • Tweets626
  • Following221
  • Followers469
16Media
Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)Photo by Greg Daniel, PhD (@gregwdaniel)
Greg Daniel, PhD retweeted
MDIC (@MDIConline) profile picture
MDIC@MDIConline29 Jul 2020
TOMORROW: Our @MDICAnnualForum continues with a discussion on access and reimbursement including an update on our HEPV initiative! Learn more and register: bit.ly/2KLay3w #MDICAPF2020 @Medtronic, @EdwardsLifesci, @CMSGov, @NHCouncil, @BCBSAssociation
Image from MDIC (@MDIConline)
3
2
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis5 Jun 2020
In this month's @Health_Affairs, @DukeMargolis scholars and researchers develop models to pay for value for high cost medical technologies healthaffairs.org/doi/full/1…
Paying For Value From Costly Medical Technologies: A Framework For Applying Value-Based Payment...

Paying For Value From Costly Medical Technologies: A Framework For Applying Value-Based Payment...

Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising spending and whether this rise is translating into higher value....

healthaffairs.org
1
3
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis20 Apr 2020
#COVIDTherapeutics webinar is live We need to identify likely target molecules, streamline testing and approval, scale up manufacturing capacity and improve #RealWorldEvidence for treatments that come to market via accelerated and emergency approval pathways
1
4
1
6
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis20 Apr 2020
Challenge of #COVIDTherapeutics early access provisions is that this removes individuals from trials. Including early access into a registry still allows for #RealWorldEvidence generation
2
1
1
Introduce yourself #GoBucks #ToughLove
Image from Ohio State Football (@OhioStateFB)
12
151
4
1,155
Stand Up, Stand Out #GoBucks #ToughLove
Image from Ohio State Football (@OhioStateFB)
26
241
14
1,038
Greg Daniel, PhD retweeted
Lisa Simpson (@DrSimpsonHSR) profile picture
Lisa Simpson@DrSimpsonHSR28 Oct 2019
Another great discussion table. Glad to reconnect w Greg Daniel now at @EdwardsLifesci n meet Megan Coder from @DTXAlliance Need guidance on #ptpreferences mst, transparency on models used in #ValueAssessment #PuttingPatientsFirst @NHCouncil
Image from Lisa Simpson (@DrSimpsonHSR)
1
1
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis23 Jul 2019
Read the most recent white paper bit.ly/2YlL9pS to learn about how @FDA can better ensure drug safety through improved approaches to risk communication. @gregwdaniel @sarah_m_sheehan @DusetzinaS @CBGood23 @lillypad @jsross119
3
5
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis17 Jul 2019
Dr. Jacqueline Corrigan-Curay @US_FDA provides the opening remarks at the Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations public workshop
1
1
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis11 Jul 2019
Thank you to all of our speakers and to all of you who attended the workshop physically and via webcast! We will be continuing the discussion tomorrow at 9am with key takeaways from today. #RWEregulatory
1
2
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis6 May 2019
1/4 Out today from @dukemargolis/@LeavittPartners in @Health_Affairs: study of factors influencing #AccountableCareOrganization (ACO) survival in #Medicare's flagship alternative to fee-for-service, #MSSP. @WillBleser @DavidMuhlestein #HealthPolicy bit.ly/2Jl0gYG
Image from Duke-Margolis (@DukeMargolis)
1
15
4
29
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis22 May 2019
We need new drugs and vaccines for diseases faced by people in tropical climates, including soldiers. At the Walter Reed Army Institute of Research (@WRAIR), Monika Schneider and @dave_ridley of @dukemargolis discussed incentives for companies developing drugs and vaccines.
Image from Duke-Margolis (@DukeMargolis)
7
1
13
Martin Burruano of @IH_news and Bernie Good of @UPMCHealthPlan discussing Rx outcomes-based contracting at #ACHPSpring19.
Image from Alliance of Community Health Plans (ACHP) (@_ACHP)
1
1
2
Greg Daniel, PhD retweeted
Jen Graff (@Jennifersgraff) profile picture
Jen Graff@Jennifersgraff22 May 2019
CMS finalized rules allowing Medicare Advantage plans to use step therapy for Part B drugs. What do provider groups and states say are good practices? Stop by to see @npcnow and @dukemargolispostdoc @tkarmarkar89 at Poster E22 #ISPORAnnual
Taruja Karmarkar, PhD, MHS (@TarujaKarmarkar) profile pictureTaruja Karmarkar, PhD, MHS@TarujaKarmarkar21 May 2019
Interested in principles and legislation on step therapy practices? Grab some food at the #ISPORannual reception and come chat! @npcnow @ISPORorg
Image from Taruja Karmarkar, PhD, MHS (@TarujaKarmarkar)
2
3
6
Greg Daniel, PhD retweeted
Kevin Outterson (@koutterson) profile picture
Kevin Outterson@koutterson16 Apr 2019
We now know that successful push incentives that end at FDA approval can still result in Chapter 11 absent antibiotic pull incentives. Large $$ needed. Been saying this for years; sad to be right. – at Taizé, France
Roland Pease (@PeaseRoland) profile pictureRoland Pease@PeaseRoland15 Apr 2019
Replying to @koutterson
@achaogen 's Kenneth Hillan was in my 2nd programme "Restarting the Antibiotic Pipeline", alongside you (and Lynn Silver), discussing the dire market situation for new compounds. This news seems to underline the message. bbc.co.uk/programmes/b05n8yr…
6
13
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis8 Apr 2019
Check out our new @HIMSS blog post by Christina Silcox & @gregwdaniel outlining key #policy needs for effective #AI innovation, regulation, & adoption: bit.ly/2YL2qGf
6
5
Several planned guidances released by @US_FDA on fitness of real world #data to support #regulatory decision making. #pctGR @gregwdaniel @dukemargolis
Image from PCT Grand Rounds (@PCTGrandRounds)
6
5
Join us tomorrow (3/15/19) at 1PM EST for #pctGR to hear @gregwdaniel of @dukemargolis discuss #realworldevidence & updates on informing #policy. bit.ly/2TEtMPC
Image from PCT Grand Rounds (@PCTGrandRounds)
3
1
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis23 Jan 2019
@dukemargolis says integrating #AI into #healthcare has the potential to improve patient outcomes, reduce costs, & enhance work-life balance for healthcare providers-- AFTER we address some #regulatory & #legal challenges. #ClinicalDecisionSupport #ArtificialIntelligence
3
1
1
Greg Daniel, PhD retweeted
Duke-Margolis (@DukeMargolis) profile picture
Duke-Margolis@DukeMargolis15 Jan 2019
Duke-Margolis’ Gregory W. Daniel Named New Editor-In-Chief of DIA’s Therapeutic Innovation & Regulatory Science. @gregwdaniel

1
4
Load more